P
Peter Altevogt
Researcher at Heidelberg University
Publications - 35
Citations - 2244
Peter Altevogt is an academic researcher from Heidelberg University. The author has contributed to research in topics: Myeloid-derived Suppressor Cell & Cancer. The author has an hindex of 15, co-authored 35 publications receiving 1312 citations. Previous affiliations of Peter Altevogt include German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Christopher Groth,Christopher Groth,Xiaoying Hu,Xiaoying Hu,Rebekka Weber,Rebekka Weber,Viktor Fleming,Viktor Fleming,Peter Altevogt,Peter Altevogt,Jochen Utikal,Jochen Utikal,Viktor Umansky,Viktor Umansky +13 more
TL;DR: The current state of knowledge on the origin and function of MDSCs in cancer is analyzed, with a special emphasis on the immunosuppressive pathways pursued by M DSCs to inhibit T cell functions, resulting in tumour progression.
Journal ArticleDOI
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.
Rebekka Weber,Rebekka Weber,Viktor Fleming,Viktor Fleming,Xiaoying Hu,Xiaoying Hu,Vasyl S. Nagibin,Vasyl S. Nagibin,Christopher Groth,Christopher Groth,Peter Altevogt,Peter Altevogt,Jochen Utikal,Jochen Utikal,Viktor Umansky,Viktor Umansky +15 more
TL;DR: Accumulating evidence demonstrates that the frequency and immunosuppressive function of MDSC in cancer patients can be used as a predictive marker for therapy response, and combination strategies for M DSC targeting together with ICI are provided to improve their therapeutic efficiency incancer patients.
Journal ArticleDOI
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
Viktor Fleming,Viktor Fleming,Xiaoying Hu,Xiaoying Hu,Rebekka Weber,Rebekka Weber,Vasyl S. Nagibin,Vasyl S. Nagibin,Christopher Groth,Christopher Groth,Peter Altevogt,Peter Altevogt,Jochen Utikal,Jochen Utikal,Viktor Umansky,Viktor Umansky +15 more
TL;DR: Different therapeutic approaches on MDSC targeting to overcome immunosuppressive TME and enhance the efficiency of current tumor immunotherapies are discussed.
Journal ArticleDOI
Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma
Veronica Huber,Viviana Vallacchi,Viktor Fleming,Xiaoying Hu,Agata Cova,Matteo Dugo,Eriomina Shahaj,Roberta Sulsenti,Elisabetta Vergani,Paola Filipazzi,Angela De Laurentiis,Luca Lalli,Lorenza Di Guardo,Roberto Patuzzo,Barbara Vergani,Elena Casiraghi,Mara Cossa,Ambra Vittoria Gualeni,Valentina Bollati,Flavio Arienti,Filippo de Braud,Luigi Mariani,Antonello Villa,Peter Altevogt,Viktor Umansky,Monica Rodolfo,Licia Rivoltini +26 more
TL;DR: MDSC-related miRs represent an indicator of MDSC activity in cancer patients and a potential blood marker of a poor immunotherapy outcome.
Journal ArticleDOI
SOX2 in development and cancer biology.
Daniel Novak,Laura Hüser,Jonathan J. Elton,Viktor Umansky,Peter Altevogt,Jochen Utikal,Jochen Utikal +6 more
TL;DR: Findings indicate that studying the role of SOX2 in the context of cancer progression could lead to the development of new therapeutic options and the resistance towards cancer therapies is summarized.